Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 7/20 | 0.55 |
| ▸ | NPY4R | P50391 | 7/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.55 |
| ▸ | NPY1R | P25929 | 5/20 | 0.55 |
| ▸ | TFPI | P10646 | 4/20 | 0.55 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.54 |
| ▸ | CALCR | P30988 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30431273 | 0.87 | NMUR2 (0.65) | NMUR2NMUR1EP300HIF1AKDM1A | |
| SCHEMBL32677401 | 0.84 | NMUR2 (0.62) | NMUR2NMUR1EP300HIF1AKDM1A | |
| SCHEMBL30432104 | 0.84 | TFPI (0.69) | NMUR2NMUR1KDM1AMAOBKDM5A | |
| SCHEMBL31295894 | 0.84 | NMUR2 (0.60) | NMUR2NMUR1KDM1AMAOBKDM5A | |
| SCHEMBL30429119 | 0.83 | NPY2R (0.67) | NMUR2NMUR1KDM1ANPY2RNPY4R | |
| SCHEMBL30495778 | 0.83 | NPY2R (0.69) | NMUR2NMUR1KDM1AMAOBKDM5A | |
| SCHEMBL31183026 | 0.83 | NPY2R (0.64) | NMUR2NMUR1EP300HIF1AKDM1A | |
| SCHEMBL30512535 | 0.83 | NMUR2 (0.63) | NMUR2NMUR1KDM1AMAOBKDM5A | |
| SCHEMBL30883233 | 0.83 | NMUR2 (0.68) | NMUR2NMUR1EP300HIF1ANPY2R | |
| SCHEMBL30432260 | 0.83 | NPY2R (0.61) | KDM1ANPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599679-B2 | Circular RNA compositions | ORNA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12590138-B2 | Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64 | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260048125-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCERS | A2 BIOTHERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12544440-B2 | IL-36 secreting immunoresponsive cells and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260028386-A1 | COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2026-01-29 | — | — | US | disclosed |
| US-12460199-B2 | Modular polypeptide libraries and methods of making and using same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025202653-A1 | T-CELL THERAPY TARGETTING MUTANT CALRETICULIN | UCL BUSINESS LTD (GB) | 2025-10-02 | — | — | WO | disclosed |
| US-20250262324-A1 | Circular RNA Compositions | ORNA THERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4504799-A1 | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING | Fate Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-116589595-B | Targeting MRSA chimeric antigen receptor, drug delivery body, CAR-macrophage and application | 山东大学 | 2024-07-19 | — | — | CN | disclosed |
| EP-4069748-A1 | MODULATORS OF THE IMMUNE ESCAPE MECHANISM FOR UNIVERSAL CELL THERAPY | Vycellix, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022187289-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF RETROVIRAL PARTICLES | EXUMA BIOTECH CORP. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022173949-A1 | POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE | WUGEN, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4041297-A1 | COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR T CELLS TO TREAT ACUTE MYELOID LEUKEMIA | The Trustees of The University of Pennsylvania (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220220188-A1 | COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-07-14 | — | — | US | disclosed |
| EP-4022035-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | EXUMA BIOTECH CORP. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4017530-A1 | IMMUNE CELLS FOR ADOPTIVE CELL THERAPIES | Board of Regents, The University of Texas System (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4004043-A1 | CAR-CD123 VECTOR AND USES THEREOF | Ospedale Pediatrico Bambino Gesù (IT) | 2022-06-01 | — | — | EP | disclosed |
| EP-4004049-A1 | CHIMERIC ANTIGEN RECEPTORS WITH MAGE-A4 SPECIFICITY AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220160771-A1 | FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USING THE SAME | ELEVATEBIO TECHNOLOGIES, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599679-B2 | Circular RNA compositions | BCL6, BCL9, BCL6B | NMUR2 2317/4885NMUR1 2191/4885EP300 4679/4885 |
| US-12544440-B2 | IL-36 secreting immunoresponsive cells and uses thereof | IL36G, ICOS, IL2 | NMUR2 1099/4885NMUR1 929/4885EP300 1573/4885 |
| US-20260028386-A1 | COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS | F8, IL2RA, ICOS | NMUR2 2140/4885NMUR1 2789/4885EP300 4851/4885 |
| US-20250262324-A1 | Circular RNA Compositions | BCL9, IGF2BP1, BCL6 | NMUR2 3691/4885NMUR1 3254/4885EP300 4364/4885 |
| US-20260048125-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCERS | CD47, SELPLG, LTK | NMUR2 522/4885NMUR1 620/4885EP300 4111/4885 |
| US-12590138-B2 | Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64 | FCGR1A, FCGR2A, FCGR3B | NMUR2 2391/4885NMUR1 2157/4885EP300 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.